{"status": "Ok", "redirect_url": "https://news.bms.com/news/details/2026/Bristol-Myers-Squibb-Announces-CELMoD-Mezigdomide-Reduces-Risk-of-Disease-Progression-or-Death-by-More-than-50-vs--Standard-of-Care-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx", "message": "News view counter 766696 successfully enlarged"}